医学临床研究
  2025年4月5日 星期六           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2024, Vol. 41 Issue (5): 725-728    DOI: 10.3969/j.issn.1671-7171.2024.05.023
  论著 本期目录 | 过刊浏览 | 高级检索 |
葛酮通络胶囊联合丁苯酞治疗后循环急性脑梗死的疗效及对血清TGF-β1/Smad3信号通路相关蛋白表达、血小板相关因子的影响
徐小隔, 李静雪, 魏孟丽
郑州大学附属郑州中心医院,河南 郑州 450000
The Therapeutic Effect of Getong Tongluo Capsule Combined with Butylphthalide in the Treatment of Acute Posterior Circulation Infarction and its Effect on Serum TGF-β1/Smad3 Signaling Pathway and Platelet Related Factors
XU Xiaoge, LI Jingxue, WEI Mengli
Zhengzhou Central Hospital Affiliated to Zhengzhou University,Zhengzhou Henan 450000
全文: PDF (1181 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨葛酮通络胶囊联合丁苯酞治疗后循环急性脑梗死(POCI)的疗效及对血清转化生长因子β1(TGF-β1)/Smad3信号通路相关蛋白表达、血小板相关因子的影响。【方法】回顾性分析2020年1月至2023年1月本院收治的114例POCI患者的临床资料,根据治疗方法的不同将其分为观察组和对照组,每组57例。对照组采用丁苯酞治疗,观察组采用葛酮通络胶囊+丁苯酞治疗。比较两组疗效、神经功能缺损评分(NIHSS)、Barthel指数、血清TGF-β1/Smad3信号通路相关蛋白表达(Smad3、TGF-β1、Smad1)、血小板相关因子[血管内皮细胞生长因子(VEGF)、血小板活化因子(PAF)、血管紧张素Ⅱ(AngⅡ)、基质金属蛋白酶9(MMP-9)]、炎症反应指标[可溶性肿瘤坏死因子相关凋亡诱导配体(sTRAIL)、超敏C反应蛋白(hs-CRP)、单核细胞趋化蛋白-1(MCP-1)]。【结果】观察组有效率为94.74%(54/57),高于对照组的80.70%(46/57),差异有统计学意义(χ2=5.211,P=0.022)。治疗后,两组NIHSS评分低于治疗前,且观察组低于对照组,Barthel指数评分高于治疗前,且观察组高于对照组(P<0.05)。治疗后,两组Smad3、TGF-β1、Smad1低于治疗前,且观察组低于对照组(P<0.05)。治疗后,两组血清VEGF水平高于治疗前,且观察组高于对照组,血清PAF、AngⅡ、MMP-9水平低于治疗前,且观察组低于对照组(P<0.05)。治疗后,两组血清hs-CRP、sTRAIL、MCP-1水平低于治疗前,且观察组低于对照组(P<0.05)。【结论】葛酮通络胶囊联合丁苯酞可抑制TGF-β1/Smad3信号通路相关蛋白表达和血小板活化,减轻炎症反应,改善患者神经功能。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
徐小隔
李静雪
魏孟丽
关键词 脑梗死急性病苯丙酮类/治疗应用转化生长因子β1/血液血小板    
Abstract:【Objective】To explore the therapeutic effect of Getong Tongluo capsule combined with butylphthalide in the treatment of in posterior circulation infarction (POCI),and its effects on the serum transforming growth factor-β1 (TGF-β1)/Smad3 signaling pathway and platelet related factors.【Methods】A retrospective analysis was conducted on the clinical data of 114 POCI patients admitted to our hospital from January 2020 to January 2023. According to different treatment methods, they were divided into the observation group and the control group, with 57 cases in each group. The control group was treated with butylphthalide, while the observation group was treated with Getong Tongluo capsules and butylphthalide. Two groups were compared in terms of efficacy, National Institute of Health stroke scale (NIHSS),Barthel index, serum TGF -β1/Smad3 signaling pathway related protein expression (Smad3,TGF-β1, Smad1),platelet related factors [vascular endothelial growth factor (VEGF), platelet activating factor (PAF), angiotensin Ⅱ(Ang Ⅱ), matrix metalloproteinase-9 (MMP-9)], inflammatory response indicators [soluble tumor necrosis factor related apoptosis inducing ligand (sTRAIL), hypersensitive C-reactive protein (hs-CRP), monocyte chemotactic protein-1 (MCP-1)].【Results】The effective rate of the observation group was 94.74%(54/57), which was higher than the control group's 80.70%(46/57), and the difference was statistically significant (χ2=5.211, P=0.022). After treatment, the NIHSS scores in both groups were lower than before treatment, and the observation group was lower than the control group. The Barthel index score was higher than that before treatment, and the observation group was higher than the control group (P<0.05). After treatment, Smad3,TGF-β1 and Smad1 of the two groups were lower than those before treatment, and the observation group was lower than the control group (P<0.05). After treatment, the serum VEGF levels in both groups were higher than those before treatment, and the observation group was higher than the control group. The level of the serum PAF,Ang Ⅱ and MMP-9 was lower than those before treatment, and the observation group was lower than the control group (P<0.05). After treatment, the levels of serum hs-CRP, sTRAIL and MCP-1 of the two groups were lower than those before treatment, and the observation group was lower than the control group (P<0.05).【Conclusion】The combination of Getong Tongluo capsules and butylphthalide can inhibit the expression of TGF-β1/Smad3 signaling pathway related proteins, inhibit platelet activation, alleviate inflammatory response, and improve patient neurological function.
Key wordsBrain Infarction    Acute Disease    Propiophenones/TU    Transforming Growth Factor beta1/BL    Blood Platelets
收稿日期: 2023-08-11     
中图分类号:  R743.33  
引用本文:   
徐小隔, 李静雪, 魏孟丽. 葛酮通络胶囊联合丁苯酞治疗后循环急性脑梗死的疗效及对血清TGF-β1/Smad3信号通路相关蛋白表达、血小板相关因子的影响[J]. 医学临床研究, 2024, 41(5): 725-728.
XU Xiaoge, LI Jingxue, WEI Mengli. The Therapeutic Effect of Getong Tongluo Capsule Combined with Butylphthalide in the Treatment of Acute Posterior Circulation Infarction and its Effect on Serum TGF-β1/Smad3 Signaling Pathway and Platelet Related Factors. JOURNAL OF CLINICAL RESEARCH, 2024, 41(5): 725-728.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.05.023     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I5/725
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn